이 포스팅은 쿠팡 파트너스 활동의 일환으로, 이에 따른 일정액의 수수료를 제공받습니다.
On April 2, 2026, President Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceutical imports into the United States, invoking Section 232 of the Trade Expansion Act on national security grounds. The sweeping measure targets foreign-made branded drugs and their active ingredients, marking one of the most aggressive pharmaceutical trade actions in U.S. history.
Key Details of the Pharmaceutical Tariff
Under the new order, tariffs of up to 100% will apply to patented pharmaceutical products and their ingredients sourced from most countries. However, significant exceptions exist: imports from the European Union, Japan, South Korea, and Switzerland/Liechtenstein will face a reduced rate of 15%, reflecting existing trade alliances and diplomatic considerations.
The timeline for compliance varies by company size. Large pharmaceutical companies have 120 days to adjust supply chains, while smaller companies are granted 180 days before the tariffs take full effect. This grace period is intended to limit immediate disruption, though analysts warn that higher drug costs could still hit consumers well before year-end.
Steel, Aluminum, and Copper Tariffs Also Tightened
Alongside the pharmaceutical announcement, Trump also overhauled existing metals tariffs. Articles made entirely or almost entirely of aluminum, steel, or copper will now face a flat 50% tariff calculated on the full price paid by American buyers — not the production cost declared by exporters. Derivative articles substantially made of these materials face a 25% tariff. The White House cited foreign exporters gaming the system by artificially deflating declared production costs as justification.
Supreme Court Complicates Tariff Landscape
The new tariffs arrive against a turbulent backdrop. Six weeks prior to the April 2 announcement, the U.S. Supreme Court ruled that the Trump administration had overstepped its authority with certain previously imposed tariffs. As a result, approximately $166 billion in tariffs must be refunded to importers. Customs and Border Protection officials have stated they hope to finalize a refund plan by mid-April 2026.
Economic Fallout: Manufacturing Jobs and Inflation
The broader tariff program initiated in April 2025 has had measurable economic consequences. U.S. manufacturers have shed approximately 89,000 jobs since the original worldwide tariffs took effect, with factories continuing to face elevated input costs. Consumer advocates warn that 100% tariffs on patented drugs — which include blockbuster medications for conditions such as diabetes, cancer, and heart disease — could significantly increase out-of-pocket costs for patients, particularly those without comprehensive insurance coverage.
Industry and Global Reactions
Major pharmaceutical companies based in Ireland, India, and China face the steepest exposure to the new 100% rate. European and Japanese drugmakers, benefiting from the 15% preferential rate, are expected to gain a competitive edge in the U.S. market. Industry trade group PhRMA warned that the tariffs risk disrupting critical medicine supplies and increasing costs for American patients.
China, which supplies a large share of active pharmaceutical ingredients (APIs) globally, faces the full 100% tariff and is expected to respond through diplomatic channels. India, another major API supplier, has called for WTO consultations.
What Happens Next
With 120-180 days before full implementation, the pharmaceutical industry is racing to restructure supply chains and explore domestic manufacturing alternatives. Several U.S. governors have signaled interest in fast-tracking permits for domestic drug manufacturing facilities. Economists remain divided: supporters argue the tariffs will accelerate domestic pharmaceutical manufacturing, while critics contend consumers will bear higher drug prices long before any reshoring benefits materialize.
Frequently Asked Questions
Q: Will the 100% pharmaceutical tariff immediately raise drug prices?
A: Not immediately. Large companies have 120 days and smaller companies 180 days before the tariffs take effect. However, analysts expect prices to rise once tariffs kick in, particularly for branded patented drugs manufactured in countries like China and India that do not benefit from the preferential 15% rate.
Q: Which countries are exempt from the 100% pharmaceutical tariff?
A: The EU, Japan, South Korea, and Switzerland/Liechtenstein receive a reduced 15% tariff rate rather than the full 100%. All other trading partners, including China, India, Canada, and Mexico, face the full 100% tariff on patented pharmaceutical products.
This article was written by AI based on publicly available information.
